Viral Genetics exercised its option for an exclusive, worldwide license to develop cancer therapies using the university's metabolic disruption technology. The technology blocks tumor cells' ability to generate energy from glucose or fatty acids. Financial...

Viral Genetics now has rights to the university's IP to target peptides to treat all immune-related disorders. Previously, under a 2008 deal, Viral Genetics' use of the IP was limited to the diagnosis and treatment...

Viral Genetics created a wholly owned subsidiary called MetaCytoLytics Inc. to develop technology from the universities which blocks a tumor cell's ability to generate energy from glucose or fatty acids. The company is completing negotiations...